Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer
Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity...
Saved in:
| Published in | Frontiers in immunology Vol. 15; p. 1391524 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
21.05.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1664-3224 1664-3224 |
| DOI | 10.3389/fimmu.2024.1391524 |
Cover
Loading…
| Abstract | Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity.
Using advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively.
55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined.
Our findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies. |
|---|---|
| AbstractList | BackgroundCervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity.MethodsUsing advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively.Results55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined.ConclusionOur findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies. Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity.BackgroundCervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity.Using advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively.MethodsUsing advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively.55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined.Results55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined.Our findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies.ConclusionOur findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies. Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single biomarker is inadequate to predict CC prognosis or identify CC patients likely to benefit from immunotherapy, presumably owing to tumor complexity and heterogeneity. Using advanced Olink proteomics, we analyzed 92 oncology-related proteins in plasma from CC patients receiving immunotherapy, based upon the comparison of protein expression levels of pre-therapy with those of therapy-Cycle 6 in the partial response (PR) group and progressive disease (PD) group, respectively. 55 proteins were identified to exhibit differential expression trends across pre-therapy and post-therapy in both PR and PD groups. Enriched GO terms and KEGG pathways were associated with vital oncological and immunological processes. A logistic regression model, using 5 proteins (ITGB5, TGF-α, TLR3, WIF-1, and ERBB3) with highest AUC values, demonstrated good predictive performance for prognosis of CC patients undergoing immunotherapy and showed potential across different cancer types. The effectiveness of these proteins in prognosis prediction was further validated using TCGA-CESC datasets. A negative correlation and previously unidentified roles of WIF-1 in CC immunotherapy was also first determined. Our findings reveal multi-biomarker profiles effectively predicting CC prognosis and identifying patients benefitting most from immunotherapy, especially for those with limited treatment options and traditionally poor prognosis, paving the way for personalized immunotherapeutic treatments and improved clinical strategies. |
| Author | Gao, Rongrong Peng, Shenjie Zhu, Youwei Fu, Jun Shi, Huijuan Zhang, Xu Yang, Liuke Zhang, Tiancheng Li, Jin He, Gaoyang Wu, XiaoHua Chen, Xuwen |
| AuthorAffiliation | 4 Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , China 9 LC-Bio Technology Co., Ltd , Hangzhou , China 8 Shanghai Kelin Clinical Bioinformatics Institute , Shanghai , China 2 Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies , Shanghai , China 3 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University , Shanghai , China 6 Clinical Center of Bio-Therapy at Zhongshan Hospital & Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University , Shanghai , China 5 College of Plant Protection, Nanjing Agricultural University , Nanjing , China 10 Shanghai Medical College of Fudan University, Fudan University , Shanghai , China 1 NHC Key Laboratory of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedic |
| AuthorAffiliation_xml | – name: 3 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University , Shanghai , China – name: 5 College of Plant Protection, Nanjing Agricultural University , Nanjing , China – name: 1 NHC Key Laboratory of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies , Shanghai , China – name: 7 Clinical Center for Biotherapy at Zhongshan Hospital, Fudan University , Shanghai , China – name: 2 Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies , Shanghai , China – name: 10 Shanghai Medical College of Fudan University, Fudan University , Shanghai , China – name: 9 LC-Bio Technology Co., Ltd , Hangzhou , China – name: 4 Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , China – name: 8 Shanghai Kelin Clinical Bioinformatics Institute , Shanghai , China – name: 6 Clinical Center of Bio-Therapy at Zhongshan Hospital & Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University , Shanghai , China |
| Author_xml | – sequence: 1 givenname: Jin surname: Li fullname: Li, Jin – sequence: 2 givenname: Xu surname: Zhang fullname: Zhang, Xu – sequence: 3 givenname: Liuke surname: Yang fullname: Yang, Liuke – sequence: 4 givenname: Youwei surname: Zhu fullname: Zhu, Youwei – sequence: 5 givenname: Rongrong surname: Gao fullname: Gao, Rongrong – sequence: 6 givenname: Tiancheng surname: Zhang fullname: Zhang, Tiancheng – sequence: 7 givenname: Xuwen surname: Chen fullname: Chen, Xuwen – sequence: 8 givenname: Jun surname: Fu fullname: Fu, Jun – sequence: 9 givenname: Gaoyang surname: He fullname: He, Gaoyang – sequence: 10 givenname: Huijuan surname: Shi fullname: Shi, Huijuan – sequence: 11 givenname: Shenjie surname: Peng fullname: Peng, Shenjie – sequence: 12 givenname: XiaoHua surname: Wu fullname: Wu, XiaoHua |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38835778$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkstu3CAUhlGVqkmmeYEuKi-78ZSrbVZVFfUSKVI36RphOExIbXDBHimv0ScunplECUICDh__4cB_ic5CDIDQB4K3jHXys_PjuGwppnxLmCSC8jfogjQNrxml_OzF_Bxd5fyAS-OSMSbeoXPWdUy0bXeB_t3ptIMZbDWlOEMcvcm1LYE0-lCi4zLMvu59HHX6A2mlnB8gVxb2MMSpIGbQOXvny66LB2IXYva50sFW6y1DnO8h6emxSpCnGHI5Hl2l7V4HswpA2nujh8qs6_QevXV6yHB1Gjfo9_dvd9c_69tfP26uv97WhlM815xhaRw12joniex518kWStXOMd0AlkKIlnd27a3mXBSoa0UDIA3FFrMNujnq2qgf1JR8KfFRRe3VIRDTTuk0ezOAopz0AlNraXlU6YTUwHDfkI6blpm-L1pfjlrT0o9gDYQ56eGV6Oud4O_VLu4VIYR3lMmi8OmkkOLfBfKsRp8NDIMOEJesGC6ZKRUF3qCPL5M9Z3n61QLQI2BSzDmBe0YIVqt71ME9anWPOrmH_Qe5DrzZ |
| Cites_doi | 10.1002/pmic.202100170 10.5732/cjc.010.10456 10.2217/imt.12.92 10.1016/j.ctrv.2019.101911 10.1200/JCO.2016.72.1985 10.1002/ijc.31814 10.1016/S1470-2045(18)30765-4 10.18388/abp.2020_6700 10.15252/emmm.201404976 10.1093/nar/gkv007 10.1111/imm.13664 10.1056/NEJMoa1709684 10.1016/S1470-2045(18)30700-9 10.3389/fcell.2021.816230 10.3322/caac.21660 10.1016/S1470-2045(16)30098-5 10.1002/ijc.25400 10.1158/2159-8290.CD-15-1545 10.2174/1381612820666140826153347 10.1126/scitranslmed.aah3560 10.3390/cancers11101425 10.1136/jitc-2021-003497 10.1016/j.ccell.2019.01.003 10.1111/jcmm.15990 10.1371/journal.pgen.1007200 10.1016/S0090-8258(22)01243-4 10.1158/1078-0432.CCR-19-3014 10.1038/s41598–022-11415–1 10.1038/onc.2015.52 10.1093/bioinformatics/bti623 10.1016/j.mcpro.2021.100168 10.1056/NEJMoa1801946 10.1002/ijc.33588 10.3389/fimmu.2021.610789 10.1097/01.ogx.0000526010.06041.5e 10.1158/2159-8290.CD-18-0367 10.1002/ijc.29283 10.1186/s12943–019-1128–6 10.1158/1078-0432.CCR-20-4459 10.1200/JCO.2017.76.6212 10.1097/CAD.0000000000001050 10.4103/0366–6999.156795 10.1016/j.critrevonc.2019.01.006 10.1038/s41422-020-0323-8 10.1007/s11912–014-0402–4 10.1056/NEJMc1509660 10.1016/j.cell.2016.02.065 10.3322/caac.21763 10.1016/j.clon.2019.07.003 10.3389/fonc.2019.00904 10.3389/fimmu.2017.01897 10.1056/NEJMoa1200690 10.1186/bcr3349 10.21873/cgp.20317 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu. Copyright © 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu |
| Copyright_xml | – notice: Copyright © 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu. – notice: Copyright © 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2024.1391524 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_241b502dd26649f59ae30b6184c73cbb PMC11148239 38835778 10_3389_fimmu_2024_1391524 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c420t-4309cf2cadff919b48897e166ff3a6e09555748d48d47a4459198756ee9c20d03 |
| IEDL.DBID | M48 |
| ISSN | 1664-3224 |
| IngestDate | Wed Aug 27 01:26:21 EDT 2025 Thu Aug 21 18:34:09 EDT 2025 Thu Sep 04 22:50:16 EDT 2025 Thu Apr 03 07:07:34 EDT 2025 Tue Jul 01 01:40:41 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | immunotherapy response proteomics biomarker cervical cancer prognosis |
| Language | English |
| License | Copyright © 2024 Zhang, Li, Yang, Zhu, Gao, Zhang, Chen, Fu, He, Shi, Peng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c420t-4309cf2cadff919b48897e166ff3a6e09555748d48d47a4459198756ee9c20d03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Oscar Maiques, Queen Mary University of London, United Kingdom These authors have contributed equally to this work Edited by: Tianfang Wang, University of the Sunshine Coast, Australia Ameneh Jafari, Shahid Beheshti University of Medical Sciences, Iran |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2024.1391524 |
| PMID | 38835778 |
| PQID | 3064922582 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_241b502dd26649f59ae30b6184c73cbb pubmedcentral_primary_oai_pubmedcentral_nih_gov_11148239 proquest_miscellaneous_3064922582 pubmed_primary_38835778 crossref_primary_10_3389_fimmu_2024_1391524 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-21 |
| PublicationDateYYYYMMDD | 2024-05-21 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Strosberg (B21) 2020; 26 Sung (B2) 2021; 71 Li (B10) 2019; 81 Hergovich (B35) 2012; 14 Tang (B47) 2020; 19 Hänninen (B51) 2018; 14 Hammers (B27) 2017; 35 He (B36) 2015; 34 Liu (B31) 2021; 9 Misako (B44) 2017; 8 Xu (B46) 2015; 128 Wang (B48) 2021; 12 Chen (B12) 2016; 6 Hellmann (B20) 2018; 378 Gadducci (B16) 2019; 135 B3 Haslam (B9) 2022; 22 Ferlay (B4) 2021; 149 Scherpereel (B24) 2019; 20 Wolchok (B25) 2017; 377 Small (B1) 2017; 72 Ruggiero (B54) 2019; 11 Zhuang (B30) 2020; 24 Ritchie (B49) 2015; 43 Klose (B42) 2020; 30 Otter (B28) 2019; 31 Ramírez-Torres (B29) 2022; 19 Wakeham (B5) 2014; 16 Sing (B55) 2005; 21 Yang (B17) 2022; 10 He (B37) 2015; 7 Ro (B14) 2017; 9 Glavan (B45) 2014; 20 Janjigian (B26) 2018; 36 Halec (B41) 2018; 143 Julie (B7) 2012; 366 Gide (B15) 2019; 35 Wang (B34) 2016; 6 Hugo (B13) 2016; 165 Siegel (B57) 2023; 73 Zhang (B32) 2019; 9 Hasimu (B38) 2011; 30 Uyangaa (B50) 2023; 170 Varney (B11) 2015; 5 Daud (B40) 2011; 128 Taki (B53) 2021; 27 Antonia (B23) 2016; 17 Scott (B39) 2014; 136 Croce (B43) 2012; 4 Wik (B8) 2021; 20 Yang (B52) 2022; 12 Hodi (B19) 2018; 19 Shi (B33) 2021; 32 Wei (B6) 2018; 8 Barrington (B18) 2022; 165 Wang (B56) 2023; 70 Larkin (B22) 2015; 373 |
| References_xml | – volume: 22 year: 2022 ident: B9 article-title: Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms publication-title: Proteomics doi: 10.1002/pmic.202100170 – volume: 30 year: 2011 ident: B38 article-title: Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women publication-title: Chin J Cancer doi: 10.5732/cjc.010.10456 – ident: B3 – volume: 4 year: 2012 ident: B43 article-title: Immunotherapeutic applications of IL-15 publication-title: Immunotherapy doi: 10.2217/imt.12.92 – volume: 81 year: 2019 ident: B10 article-title: RET fusions in solid tumors publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2019.101911 – volume: 35 start-page: JCO2016721985 year: 2017 ident: B27 article-title: Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkMate 016 study publication-title: J Clin Oncol doi: 10.1200/JCO.2016.72.1985 – volume: 143 year: 2018 ident: B41 article-title: Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2 publication-title: Int J Cancer doi: 10.1002/ijc.31814 – volume: 20 year: 2019 ident: B24 article-title: Nivolumab or nivolumab plus ipilimumab in patients with relapsed Malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial (vol 20, pg 239, 2019) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30765-4 – volume: 70 year: 2023 ident: B56 article-title: WIF1 was downregulated in cervical cancer due to promoter methylation publication-title: Acta Biochim Pol doi: 10.18388/abp.2020_6700 – volume: 7 year: 2015 ident: B37 article-title: The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression publication-title: EMBO Mol Med doi: 10.15252/emmm.201404976 – volume: 43 year: 2015 ident: B49 article-title: limma powers differential expression analyses for RNA-sequencing and microarray studies publication-title: Nucleic Acids Res doi: 10.1093/nar/gkv007 – volume: 170 year: 2023 ident: B50 article-title: TLR3/TRIF pathway confers protection against herpes simplex encephalitis through NK cell activation mediated by a loop of type I IFN and IL-15 from epithelial and dendritic cells publication-title: Immunology: Off J Br Soc Immunol doi: 10.1111/imm.13664 – volume: 377 start-page: 1345 year: 2017 ident: B25 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1709684 – volume: 19 year: 2018 ident: B19 article-title: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30700-9 – volume: 9 year: 2021 ident: B31 article-title: Comprehensive analysis of the expression and prognosis for ITGBs: identification of ITGB5 as a biomarker of poor prognosis and correlated with immune infiltrates in gastric cancer publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2021.816230 – volume: 71 year: 2021 ident: B2 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 17 year: 2016 ident: B23 article-title: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30098-5 – volume: 128 year: 2011 ident: B40 article-title: Association between toll-like receptor expression and human papillomavirus type 16 persistence publication-title: Int J Cancer doi: 10.1002/ijc.25400 – volume: 6 year: 2016 ident: B12 article-title: Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade publication-title: Cancer Discovery doi: 10.1158/2159-8290.CD-15-1545 – volume: 20 year: 2014 ident: B45 article-title: The exploitation of Toll-like receptor 3 signaling in cancer therapy publication-title: Curr Pharm Des doi: 10.2174/1381612820666140826153347 – volume: 9 year: 2017 ident: B14 article-title: Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aah3560 – volume: 11 year: 2019 ident: B54 article-title: ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin publication-title: Cancers (Basel) doi: 10.3390/cancers11101425 – volume: 10 year: 2022 ident: B17 article-title: Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma publication-title: J Immunother Cancer doi: 10.1136/jitc-2021-003497 – volume: 6 start-page: 1108 year: 2016 ident: B34 article-title: Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin β5-mediated glycolysis publication-title: Am J Cancer Res – volume: 35 year: 2019 ident: B15 article-title: Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.01.003 – volume: 24 year: 2020 ident: B30 article-title: Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer publication-title: J Cell Mol Med doi: 10.1111/jcmm.15990 – volume: 14 year: 2018 ident: B51 article-title: Exome-wide somatic mutation characterization of small bowel adenocarcinoma publication-title: PLoS Genet doi: 10.1371/journal.pgen.1007200 – volume: 165 year: 2022 ident: B18 article-title: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis (025) publication-title: Gynecol Oncol doi: 10.1016/S0090-8258(22)01243-4 – volume: 26 start-page: 2019 year: 2020 ident: B21 article-title: Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-3014 – volume: 12 start-page: 8112 year: 2022 ident: B52 article-title: ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer publication-title: Sci Rep doi: 10.1038/s41598–022-11415–1 – volume: 34 year: 2015 ident: B36 article-title: YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression publication-title: Oncogene doi: 10.1038/onc.2015.52 – volume: 21 year: 2005 ident: B55 article-title: ROCR: visualizing classifier performance in R publication-title: Bioinformatics doi: 10.1093/bioinformatics/bti623 – volume: 20 year: 2021 ident: B8 article-title: Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis publication-title: Mol Cell Proteomics doi: 10.1016/j.mcpro.2021.100168 – volume: 378 year: 2018 ident: B20 article-title: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden publication-title: N Engl J Med doi: 10.1056/NEJMoa1801946 – volume: 149 year: 2021 ident: B4 article-title: Cancer statistics for the year 2020: An overview publication-title: Int J Cancer doi: 10.1002/ijc.33588 – volume: 12 year: 2021 ident: B48 article-title: Transcription factors associated with IL-15 cytokine signaling during NK cell development publication-title: Front Immunol doi: 10.3389/fimmu.2021.610789 – volume: 5 year: 2015 ident: B11 article-title: VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner publication-title: Am J Cancer Res – volume: 72 year: 2017 ident: B1 article-title: Cervical cancer: A global health crisis publication-title: Obstetrical Gynecological Survey doi: 10.1097/01.ogx.0000526010.06041.5e – volume: 8 start-page: 2159 year: 2018 ident: B6 article-title: Fundamental mechanisms of immune checkpoint blockade therapy publication-title: Cancer Discovery doi: 10.1158/2159-8290.CD-18-0367 – volume: 136 year: 2014 ident: B39 article-title: Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response publication-title: Int J Cancer doi: 10.1002/ijc.29283 – volume: 19 year: 2020 ident: B47 article-title: m(6)A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling publication-title: Mol Cancer doi: 10.1186/s12943–019-1128–6 – volume: 27 start-page: 2020 year: 2021 ident: B53 article-title: Tumor immune microenvironment during epithelial-mesenchymal transition publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-4459 – volume: 36 year: 2018 ident: B26 article-title: CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.6212 – volume: 32 year: 2021 ident: B33 article-title: Integrin β5 enhances the Malignancy of human colorectal cancer by increasing the TGF-β signaling publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000001050 – volume: 128 year: 2015 ident: B46 article-title: Role of wnt inhibitory factor-1 in inhibition of bisdemethoxycurcumin mediated epithelial-to-mesenchymal transition in highly metastatic lung cancer 95D cells publication-title: Chin Med J (Engl) doi: 10.4103/0366–6999.156795 – volume: 135 year: 2019 ident: B16 article-title: Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables publication-title: Crit Rev Oncology/Hematology doi: 10.1016/j.critrevonc.2019.01.006 – volume: 30 start-page: 1 year: 2020 ident: B42 article-title: Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity publication-title: Cell Res doi: 10.1038/s41422-020-0323-8 – volume: 16 year: 2014 ident: B5 article-title: The burden of HPV-associated anogenital cancers publication-title: Curr Oncol Rep doi: 10.1007/s11912–014-0402–4 – volume: 373 year: 2015 ident: B22 article-title: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMc1509660 – volume: 165 start-page: 35 year: 2016 ident: B13 article-title: Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma publication-title: Cell doi: 10.1016/j.cell.2016.02.065 – volume: 73 year: 2023 ident: B57 article-title: Cancer statistics, 2023 publication-title: CA Cancer J Clin doi: 10.3322/caac.21763 – volume: 31 year: 2019 ident: B28 article-title: The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer publication-title: Clin Oncol (Royal Coll Radiologists (Great Britain)) doi: 10.1016/j.clon.2019.07.003 – volume: 9 year: 2019 ident: B32 article-title: Integrin beta 5 is a prognostic biomarker and potential therapeutic target in glioblastoma publication-title: Front Oncol doi: 10.3389/fonc.2019.00904 – volume: 8 year: 2017 ident: B44 article-title: Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy publication-title: Front Immunol doi: 10.3389/fimmu.2017.01897 – volume: 366 year: 2012 ident: B7 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 – volume: 14 start-page: 326 year: 2012 ident: B35 article-title: YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer publication-title: Breast Cancer Res Bcr doi: 10.1186/bcr3349 – volume: 19 year: 2022 ident: B29 article-title: Quantitative proteomic analysis of cervical cancer tissues identifies proteins associated with cancer progression publication-title: Cancer Genomics Proteomics doi: 10.21873/cgp.20317 |
| SSID | ssj0000493335 |
| Score | 2.3827753 |
| Snippet | Cervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A single... BackgroundCervical cancer (CC) poses a global health challenge, with a particularly poor prognosis in cases of recurrence, metastasis, or advanced stages. A... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1391524 |
| SubjectTerms | Adult biomarker Biomarkers, Tumor - blood cervical cancer Female Humans Immunology Immunotherapy - methods immunotherapy response Middle Aged Prognosis proteomics Proteomics - methods Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - immunology Uterine Cervical Neoplasms - therapy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhUMilNH06j6JCb8WNrIflOSalIRTaUwK5CVmW6BbiLfs45G_kF2dG8obdUuil4Mt6tVirGWu-z_5mhrGPokkWbECmmsDU2htb--hJuQPaiL5HSE7Jyd9_tFc3-tutud1q9UWasFIeuCzcGUaY3gg5DBhJNCQDPirRU5uSYFXoe9p9BYgtMvWr4F6llClZMsjC4CzN7u7WyAel_txQUXSpdyJRLtj_N5T5p1hyK_pcvmDPJ9jIz8t0D9leHF-yZ6WR5P0r9nCdBd1x4LnuAmUaL-thUrrg2SwbrCnVntQ4Cz516l7yKWcKhwSC0bOEUZIjjqURJMGbLbkfB07_apxyte75ouhq8efzxDciAh7yroOTDPR58ZrdXH69_nJVT90W6qClWNVaCQhJBj-kBA30eGeDjU3bpqR8G6lUnbG6G-iwXmsD9LzCtDFCkGIQ6g3bH-djfMd4K5JEZu0B0Z0OTdsFDykilgrIN5VKFfu0WXn3uxTVcEhGyE4u28mRndxkp4pdkHGeRlJB7HwC3cRNbuL-5SYV-7AxrcMbiN6K-DHO10tHFAxwV-tkxd4WUz9dSnUIUK3tKtbtOMHOXHa_GWc_c5HuhoimVHD0P2Z_zA5oRUi1IJsTtr9arOMpgqFV_z77_SO2pgsc priority: 102 providerName: Directory of Open Access Journals |
| Title | Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38835778 https://www.proquest.com/docview/3064922582 https://pubmed.ncbi.nlm.nih.gov/PMC11148239 https://doaj.org/article/241b502dd26649f59ae30b6184c73cbb |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA7nieDL4W976hHBN-mZ5kfTPIioeB7C-XQL-xbSNNE9vK62u-D-G_7FzqTZw5XzTVgWtpvSNNPpfF_7zQwhL1gVtdEemGo0qpRO6dIFh8odIxVrW4DkmJx89rk-nclPczXfI9t2R3kBx2upHfaTmg3fjn_-2LwBh3-NjBPi7au4uLxcA9Xj8rjCeudc3iA3ITLVSMbOMty_mNCwEEJNuTP_2HUnPqUy_tdhz78llH_EpJM75CCDSfp2sv5dshf6e-TW1F5yc5_8Ok8y79DRVI0B84_Hssv6F9iaxIQlJuCjRmeguX_3SHMmFQzxCK4XEWInBXSLI1CYtxip6zuKZ9XnDK4NHSa1Ley-jHQrLaA-3Ytgkh5_Dw_I7OTD-fvTMvdgKL3kbFVKwYyP3LsuRlOZFvzd6FDVdYzC1QEL2Cktmw4_2kmpDD7FUHUIxnPWMfGQ7PfLPjwmtGaRA992BjCf9FXdeGdiAITlgYUKEQvycrvy9vtUasMCRUE72WQni3ay2U4FeYfGuRqJZbLThuXwxWavs3ARtIrxrgMYIk1UxgXBWuxx47XwbVuQ51vTWnArfFfi-rBcjxaJmYF7XcML8mgy9dWhRAOwVeumIM3ORbAzl91_-sXXVLq7QvrJhTn8H7N_Qm7jiqCWgVdPyf5qWIdnAJFW7VF6tADfH-fVUfKB3xTiFcw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+proteomics-determined+multi-biomarker+profiles+developed+classifier+for+prognosis+and+immunotherapy+responses+of+advanced+cervical+cancer&rft.jtitle=Frontiers+in+immunology&rft.au=Jin+Li&rft.au=Jin+Li&rft.au=Xu+Zhang&rft.au=Xu+Zhang&rft.date=2024-05-21&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1391524&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_241b502dd26649f59ae30b6184c73cbb |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |